logo-loader
viewIntegumen

Integumen subsidiary growth boosts earnings in 2018 following restructuring

In a trading update, the skincare group said revenues for 2018 were up more than 200% on the £238,000 figure for 2017

Woman scratching
Labskin's services allow companies to test their products on a human skin equivalent

Integumen PLC (LON:SKIN) said “positive results” from a major restructuring of its Labskin subsidiary had helped boost earnings in 2018.

In a trading update, the skincare group said revenues for 2018 were up more than 200% on the £238,000 figure for 2017, while its order book had increased to £247,000 from £37,000 year-on-year.

The firm added that Labskin had reported a 480% increase in sales in the second half of the year, while its STOER For Men skin products division had reached break-even in the period with recurring orders to June 2019 to maintain at or above breakeven.

Integumen also said it had removed around £1.19mln of short and long-term obligations following the disposal of its subsidiary TSPro GmbH in December.

Looking ahead, the company said results from testing of Labskin AI the integration of data analytics using the Labskin-On-A-Chip portable microbiology were expected in early Q2 2019, while additional Labskin laboratories at Integumen’s HQ in York were expected to be ready in February.

Labskin Cannabinoid (CBD) testing protocols were also being prepared and would be offered to existing and new skin-care clients with the firm already testing CBD oils with its STOER For Men product range.

Gerard Brandon, chief executive of Integumen, said the company had been “transformed to become a vertically integrated business”, adding that Labskin allowed companies to “test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies” and that the firm “no longer simply manufacture and sell skin-testing kits”.

In early trading Monday, Integumen shares were down 1.6% at 0.58p.

Quick facts: Integumen

Price: 1.58 GBX

AIM:SKIN
Market: AIM
Market Cap: £15.5 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Integumen named herein, including the promotion by the Company of Integumen in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: SkinBio signs commercial deal with chemical giant Croda

Headlines from the Proactive UK newsroom. SkinBioTherapeutics (LON:SBTX) has signed a commercial and manufacturing agreement for its Skinbiotix technology with speciality chemical giant Croda.  It is the first major deal for the product with Croda to design and manufacture a new active...

2 weeks, 1 day ago

2 min read